IO Biotech
IOBT
IOBT was delisted on the 6th of April, 2026.
0 hedge funds and large institutions have $0 invested in IO Biotech in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 12 closing their positions.
4.71% less ownership
Funds ownership: 4.71% → 0% (-4.7%)
100% less funds holding
Funds holding: 12 → 0 (-12)
100% less capital invested
Capital invested by funds: $199K → $0 (-$199K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 12
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$81.4K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$26.5K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$20K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$18.1K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$15.6K |
IOBT Hedge Fund Activity: Q2 2026 in Review
0 of the 8,280 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q2 2026, worth a combined $0 — down 100% from $199K a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of IOBT and 0 opened new positions — a net loss of 12 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Ikarian Capital, exiting entirely with an estimated $81.4K sold.
- 0 institutional investors held IO Biotech (IOBT) as of Q2 2026, down from 12 in Q1 2026.
- Funds reported $0 of IO Biotech stock for Q2 2026, down 100% quarter-over-quarter.
- 0 funds opened new IO Biotech positions in Q2 2026 and 12 closed out, a net change of -12 holders.
- The largest IO Biotech seller in Q2 2026 was Ikarian Capital, an estimated $81.4K sold.
Based on aggregated 13F filings for Q2 2026.